The abstract is read at the publisher; the summary is JClub's.
In newly diagnosed light-chain (AL) amyloidosis, adding subcutaneous daratumumab to VCd (D-VCd) improved overall survival with a hazard ratio of 0.62 after 61.4 months’ follow-up.
- Why it matters: Deeper hematologic responses are needed to slow organ decline and extend survival in AL amyloidosis, where major organ deterioration strongly limits outcomes.
- What they did: In this phase 3 trial, 388 patients were randomized to 6 cycles of VCd alone versus D-VCd, then daratumumab every 4 weeks up to 24 total cycles; overall survival was assessed at final analysis.
- The result: D-VCd also improved major organ deterioration-progression-free survival (hazard ratio 0.44) and is linked with higher cardiac and renal response rates, supporting faster organ recovery alongside survival benefit.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.